Back

Combined ARNI and SGLT2i impacts on peak tricuspid regurgitant velocity and echocardiographic probability of pulmonary hypertension

2 September 2024 (14:00 - 14:50)
Organised by: Logo
Congress Presentation Part of: Current pharmacological treatments for pulmonary hypertension Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Marco Stracqualursi

University of Milan, Milan (Italy)

8 More presentations in this session

Presentation thumbnail
Effects of beta blockers on outcome in patients with PAH with and without comorbid conditions: a Multicenter Prospective Cohort Study (BNP-PL).
Doctor M. Waligora (Krakow, PL)
Abstract Slides Video
Presentation thumbnail
The safety and efficacy of treprostinil for the treatment of pulmonary arterial hypertension: a systematic review and meta-analysis of randomized controlled trials
Mr H. Khasawneh (Irbid, JO)
Abstract Slides Video
Presentation thumbnail
Efficacy and tolerability of triple sequential combination therapies with selexipag in patients with pulmonary arterial hypertension : insights from a single-centre study
Doctor H. Tokgoz (Istanbul, TR)
Abstract Slides Video
Presentation thumbnail
Metoprolol therapy in patients with Eisenmenger syndrome (MINES) study. A single-centre, double-blinded, randomised, placebo-controlled trial
Doctor A. Pius (New Delhi, IN)
Abstract Slides Video
Presentation thumbnail
Efficacy of specific drug class therapy in pulmonary arterial hypertension associated with HIV, portal hypertension or both: a single Center experience
Doctor F. Cennerazzo (Bologna, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Current pharmacological treatments for pulmonary hypertension

The Event

Event poster

ESC Congress 2024

2 September 2024 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Heart failure and tricuspid regurgitation: the role of SGLT2 inhibitors in improving outcomes
thumbnail
Congress Presentation
A prospective interventional randomized study to assess efficacy of angiotensin receptor neprilysin inhibitor in right ventricular systolic dysfunction with normal left ventricular systolic function.
thumbnail
Congress Presentation
Did we forget ARNI in the era of SGLTi?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources